VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

     Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell NF2zdGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFE2PDNizszN NXiySoViW0GQR1XS
human NCI-H720 cell M1TmSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MULJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{KwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTZ6MjFOwG0> NIr5T3NUSU6JRWK=
JVM-2 cell MnzVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7iTY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFg{KM7:TR?= MkeyV2FPT0WU
human NCI-H69 cell M{Do[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6QTRzIN88US=> NVL3SHk5W0GQR1XS
human BV-173 cell M3;qN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE{QDZizszN MX;TRW5ITVJ?
human KU812 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\nTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI1QDhizszN Ml3LV2FPT0WU
human DU-145 cell MmjpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFjETWlKdmirYnn0bY9vKG:oIHj1cYFvKESXLUG0OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTR3NUSg{txO MoftV2FPT0WU
KARPAS-45 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGK0ZYdKdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUS4NlYh|ryP MV7TRW5ITVJ?
human AGS cell M2D4fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUWyOVEh|ryP NF\ucXlUSU6JRWK=
human MOLT-13 cell M16xVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{XEPGlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEGg{txO MlewV2FPT0WU
human NCI-H209 cell NVz5dYNET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{jocGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO M4HzW3NCVkeHUh?=
human CTV-1 cell M2\HVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHHL[XRKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQDN6OTFOwG0> NVLwU2FbW0GQR1XS
LU-139 cell MmrtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX7UcmxFUW6qaXLpeIlwdiCxZjDoeY1idiCOVT2xN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF7NEO1JO69VQ>? M3S0WHNCVkeHUh?=
ML-2 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUHJcohq[mm2aX;uJI9nKGi3bXHuJG1NNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyOlYyKM7:TR?= NITvVWdUSU6JRWK=
human K5 cell MljYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXLhOHRRUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI6OTdizszN MkXmV2FPT0WU
human SBC-1 cell MlnCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYnkU5loUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> NU[wO3JvW0GQR1XS
human COR-L88 cell NVnhZmhQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkD6TY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR6IN88US=> NID2bFRUSU6JRWK=
human KY821 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3zKZ2lvcGmkaYTpc44hd2ZiaIXtZY4hU1l6MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM6PjB|IN88US=> M1f2bXNCVkeHUh?=
human HCC2218 cell NVPDVGtUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUTVZldzUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNlE5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52OUeyPEDPxE1? Ml;zV2FPT0WU
human ECC10 cell M1HUN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGVESzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OVM5QSEQvF2= M4rEW3NCVkeHUh?=
human EW-3 cell NUfO[JRVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV\sbJJ6UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PjZzMTFOwG0> MUfTRW5ITVJ?
human EW-18 cell NX\re5NHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NG\JfZpKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44PDZ5OTFOwG0> MVLTRW5ITVJ?
human UACC-257 cell NH3GdVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV7LSlJSUW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMkCzNlYh|ryP M1qxPHNCVkeHUh?=
human G-361 cell MmTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkHpTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFk2OTlizszN NGTnb3dUSU6JRWK=
human HMV-II cell Mnz5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH7JfZBKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO NHTRdGJUSU6JRWK=
human DEL cell M1foR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMkC3NFQh|ryP M2i2WnNCVkeHUh?=
human IGROV-1 cell MoDmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{OTh6IN88US=> M4LNVnNCVkeHUh?=
human SK-OV-3 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE\2U|lKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZzNkm3JO69VQ>? M4fpPXNCVkeHUh?=
human LAMA-84 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUPKd2RxUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55MUK4OEDPxE1? NH7jbolUSU6JRWK=
human NCI-H510A cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUGwRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTJ3Mk[g{txO MWjTRW5ITVJ?
human CP66-MEL cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fWb2lvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl|NUW5JO69VQ>? M3O2PXNCVkeHUh?=
human HAL-01 cell NILQPGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPacHFKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjd7MUig{txO MWfTRW5ITVJ?
human RS4-11 cell  NFjRS5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHTlV2JKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzB3N{Og{txO NHnDblBUSU6JRWK=
human RPMI-8226 cell M1jtbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGfKZ3BKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtPFIzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwOEKzO|Yh|ryP Mn65V2FPT0WU
human NCI-H82 cell MmHZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUHOW|RpUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56OUOwOUDPxE1? MnrrV2FPT0WU
human NY cells NULLbmhpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXW4cnUzUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlc3OzdizszN M1PtOnNCVkeHUh?=
human MDA-MB-361 cell NIG4Z|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn3kTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN|YyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52M{G1PEDPxE1? M4XLV3NCVkeHUh?=
human MOLT-4 cell M3fYd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\UeZVKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlzOUOg{txO NEW4N2tUSU6JRWK=
human DU-4475 cell NYm2Wno2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUH2Z5dpUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yNUW2OUDPxE1? MlHXV2FPT0WU
human ESS-1 cell NHz5[FRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1n4UWlvcGmkaYTpc44hd2ZiaIXtZY4hTVOVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlI6OTd7IN88US=> NEPIdHBUSU6JRWK=
human NCI-H1299 cell MkLiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NI\zTYZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVI6QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUOwN|Mh|ryP NWjHeVNYW0GQR1XS
human COLO-684 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrXTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPThzNkWg{txO NIX3VJBUSU6JRWK=
human MV-4-11 cell NWjY[2VET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3jsemlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzFzOUmg{txO MVjTRW5ITVJ?
human D-542MG cell M2jad2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHnDXodKdmirYnn0bY9vKG:oIHj1cYFvKERvNUSyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN7MkeyJO69VQ>? M4DvXnNCVkeHUh?=
human A4-Fuk cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVXhRms{UW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjR|Nk[yJO69VQ>? Mof4V2FPT0WU
human HL-60 cell NVjaXFJCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVjKTGNEUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTJ{MUKg{txO NWrtS3ZyW0GQR1XS
human NCI-H526 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1jTN2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV7OECxJO69VQ>? NFfwNHhUSU6JRWK=
human L-363 cell M1;qNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEG4XIRKdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{44QTJ3MjFOwG0> M4rRZXNCVkeHUh?=
human A388 cell NYjDR|NNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEfHXGNKdmirYnn0bY9vKG:oIHj1cYFvKEF|OEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlgxOzh2IN88US=> M2rI[HNCVkeHUh?=
human MS-1 MoXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlHsTY5pcWKrdHnvckBw\iCqdX3hckBOWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64N|Q3PSEQvF2= Mm\5V2FPT0WU
human JAR cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYXJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwOES5NlMh|ryP NFnGRVFUSU6JRWK=
human TI-73 cell MnS2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{XpeWlvcGmkaYTpc44hd2ZiaIXtZY4hXElvN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlA3OjJizszN NXnMXWV6W0GQR1XS
human CTB-1 cell M2PRemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3zQVWlvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlE4QDJ3IN88US=> MlLzV2FPT0WU
human SK-NEP-1 cell NWG2dpRrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPoTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjNyM{ig{txO M3nRUHNCVkeHUh?=
human HT-29 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuPVEyOSEQvF2= NXzUWnlYW0GQR1XS
human NCI-H1092 cell MlTCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1HtSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNFkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTRwM{G4JO69VQ>? NYPVSGRKW0GQR1XS
human KMOE-2 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFL4T29KdmirYnn0bY9vKG:oIHj1cYFvKEuPT1WtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZzN{ig{txO MUTTRW5ITVJ?
human EM-2 cell NIHaSVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2HNSWlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlI5PDFizszN NY\oXlhkW0GQR1XS
human RT-112 cell NYCwWFZbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mnn5TY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4{QTh2IN88US=> NIK3TIJUSU6JRWK=
human DB cell NI\NNolIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWP2VnhmUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1Mlg2OTNizszN MlLtV2FPT0WU
human NCI-H1770 cell NFr1TXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVm5c2F1UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= NWXse|NoW0GQR1XS
human CAL-54 cell NG\SfYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGr5N5JKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3Njd|IN88US=> NGHQTI1USU6JRWK=
human NB14 cell MlPOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkPqTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUeuOlM6PSEQvF2= NHOzN|NUSU6JRWK=
human RPMI-7951 cell MojGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn;rTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUe5OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS5zN{izJO69VQ>? NYTyO|E3W0GQR1XS
human T47D cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\sTY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlI1OyEQvF2= NX3ycYFsW0GQR1XS
human A549 cell NUn0bXluT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1LVZ2lvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlI5OTFizszN MkHGV2FPT0WU
human A2780 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG\zWmVKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvQDJ{NTFOwG0> M4HZUnNCVkeHUh?=
human SK-MEL-24 cell M3f1c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\Mb5VKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN|LkCzNVEh|ryP MkLQV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID